5‐year OS · patients with epithelial ovarian cancer
Maintenance chemotherapy showed no clear difference in 5‐year OS compared with observation (moderate certainty).
1 finding from 1 review
10‐year OS · patients with epithelial ovarian cancer
Maintenance chemotherapy showed no clear difference in 10‐year OS compared with observation (moderate certainty).
1 finding from 1 review
Progression‐free survival · patients with epithelial ovarian cancer
Platin‐based maintenance chemotherapy showed no clear difference in 3‐year PFS compared with observation (moderate certainty).
3 findings from 1 review
RR 1.04 [0.86, 1.24]
3 studies · 341 participants
Moderate
RR 1.18 [0.88, 1.58]
2 studies · 219 participants
Moderate
RR 0.96 [0.65, 1.41]
2 studies · 219 participants
Moderate
Overall survival · Women with advanced (Stage II‐IV) epithelial ovarian cancer who have undergone surgery
Interferon + chemotherapy may leads to higher overall survival compared with chemotherapy alone (low certainty).
1 finding from 1 review
Nausea and vomiting · Women with advanced (Stage II‐IV) epithelial ovarian cancer who have undergone surgery
Interferon showed no clear difference in adverse event (nausea/ vomiting) compared with observation alone (low certainty).
1 finding from 1 review
Progression‐free survival · Women with advanced (Stage II‐IV) epithelial ovarian cancer who have undergone surgery
Interferon + chemotherapy may leads to higher progression‐free survival compared with chemotherapy alone (low certainty).
1 finding from 1 review
Adverse event (flu‐like symptoms) · Women with advanced (Stage II‐IV) epithelial ovarian cancer who have undergone surgery
Interferon + chemotherapy showed no clear difference in adverse event (flu‐like symptoms) compared with chemotherapy alone (low certainty).
1 finding from 1 review
Adverse effect: fatigue · Women with advanced (Stage II‐IV) epithelial ovarian cancer who have undergone surgery
Interferon + chemotherapy showed no clear difference in adverse event (fatigue) compared with chemotherapy alone (low certainty).
1 finding from 1 review
Neurotoxicity · Women with advanced (Stage II‐IV) epithelial ovarian cancer who have undergone surgery
Interferon + chemotherapy showed no clear difference in adverse event (neurotoxicity) compared with chemotherapy alone (low certainty).
1 finding from 1 review
Overall survival · Women with advanced (Stage II‐IV) epithelial ovarian cancer who have undergone surgery
Interferon showed no clear difference in overall survival compared with observation alone (low certainty).
1 finding from 1 review
Progression‐free survival · Women with advanced (Stage II‐IV) epithelial ovarian cancer who have undergone surgery
Interferon showed no clear difference in progression‐free survival compared with observation alone (low certainty).
1 finding from 1 review
Adverse event (flu‐like symptoms) · Women with advanced (Stage II‐IV) epithelial ovarian cancer who have undergone surgery
Interferon may leads to higher adverse event (flu‐like symptoms) compared with observation alone (low certainty).
1 finding from 1 review
Adverse effect: fatigue · Women with advanced (Stage II‐IV) epithelial ovarian cancer who have undergone surgery
Interferon may leads to higher adverse event (fatigue) compared with observation alone (low certainty).
1 finding from 1 review
Diarrhoea · People undergoing RT for pelvic cancer
Dietary modification probably leads to lower diarrhoea at end of treatment compared with no nutritional intervention (moderate certainty).
1 finding from 1 review
Change in weight (kg) · People undergoing RT for pelvic cancer
1 finding from 1 review
Intervention not reported
PFS¹ · women with newly diagnosed EOC (stage Ic to IV)
The intervention showed no clear difference in PFS¹ (high certainty).
1 finding from 1 review
Intervention not reported
OS² · women with newly diagnosed EOC (stage Ic to IV)
The intervention showed no clear difference in OS² (high certainty).
1 finding from 1 review
Intervention not reported
Anaemia (grade 3/4) · women with newly diagnosed EOC (stage Ic to IV)
The intervention leads to higher anaemia (grade 3/4) (high certainty).
1 finding from 1 review
Intervention not reported
Thrombocytopenia (grade 3/4) · women with newly diagnosed EOC (stage Ic to IV)
The intervention leads to higher thrombocytopenia (grade 3/4) (high certainty).
1 finding from 1 review
Intervention not reported
Alopecia (grade 2) · women with newly diagnosed EOC (stage Ic to IV)
The intervention leads to lower alopecia (grade 2) (high certainty).
1 finding from 1 review